Home

2025 PREVENT Application Period is Open

Applications are now being accepted for the NCI PREVENT Cancer Preclinical Drug Development Program (PREVENT).

Deadlines for applications are June 2nd, 2025 and November 3rd, 2025.

NCI Selects Two Assays for the Vanguard Study on Multi-Cancer Detection Tests

An illustration of a test tube filled with blood next to a clipboard.

MISSION STATEMENT

The Division of Cancer Prevention furthers the mission of the National Cancer Institute by leading, supporting, and promoting rigorous, innovative research and training to prevent cancer and its consequences to improve the health of all people.

Read more about Our Research

Latest News

Read All News

Early Career Scientist Seminars, Cancer Prevention Research Conference, Funding Opportunities and More

Upcoming Events; Funding Opportunities

May 6 | DCP Updates

Early Career Research Seminars, Cancer Cachexia Webinar, and New Cancer Treatment Tolerability Videos

Upcoming Events; Latest Videos

April 8 | DCP Updates

Cancer Detection News, TMIST Study, JNCI Monograph, and More

Latest News

March 4 | DCP Updates

Large-scale TMIST Breast Cancer Screening Trial Achieves Enrollment Goal

The Tomosynthesis Mammographic Imaging Screening Trial (TMIST) has reached its enrollment goal of 108,508 women, as announced today by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN). The study, funded by the National…

January 15 | ECOG-ACRIN Press Release

Meetings and
Events

Review All Our Meetings
and Events

Personalised Risk in Lung Screening

Date(s):
  • -
Location: Virtual via Webex

Harnessing Studies of Diet and the Gut Microbiome to Reduce Colorectal Cancer Burden

Date(s):
  • -
Location: Virtual via Webex

Diet and Nutrition for Managing Cancer Symptoms

Date(s):
  • -
Location: Virtual via Webex